Compare Main Street Capital Corporation (MAIN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs ResMed Inc. — how do they compare? Main Street Capital Corporation trades at $58.2 (market cap $5.52B), while ResMed Inc. trades at $222.17 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 5.9× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (5.39%). Which is the better fit depends on your goals.
| MAIN | RMD | |
|---|---|---|
Market Cap | $5.52B | $32.61B |
Sector | Financials | Health |
52-Week High | $67.54 | $293.73 |
52-Week Low | $49.63 | $182.82 |
Dividend Yield | 5.39% | 1.17% |
Enterprise Value | — | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $59.10, up 0.99% with a bullish technical outlook. The stock shows strong fundamentals with an 80.77% net income margin and 14.92% ROE, though Q2 2026 earnings missed estimates. Recent news highlights MAIN's dividend reliability amid sector challenges, with the company maintaining payouts while peers face cuts. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $59-60.
MAIN offers stable income with consistent dividends but faces headwinds from declining revenue projections ($592M in 2025 to $559M in 2026). Analyst consensus is cautious with 78.57% hold ratings and a $56.67 price target below current levels. Key risks include BDC sector pressure and expense growth impacting earnings coverage.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
